Monte Rosa Therapeutics (GLUE) EBIAT (2023 - 2025)
Monte Rosa Therapeutics' EBIAT history spans 3 years, with the latest figure at -$46.1 million for Q4 2025.
- For Q4 2025, EBIAT fell 443.15% year-over-year to -$46.1 million; the TTM value through Dec 2025 reached -$38.6 million, up 46.91%, while the annual FY2025 figure was -$38.6 million, 46.91% up from the prior year.
- EBIAT reached -$46.1 million in Q4 2025 per GLUE's latest filing, down from -$27.1 million in the prior quarter.
- In the past five years, EBIAT ranged from a high of $46.9 million in Q1 2025 to a low of -$46.1 million in Q4 2025.
- Average EBIAT over 3 years is -$20.6 million, with a median of -$31.1 million recorded in 2024.
- The largest YoY upside for EBIAT was 246.66% in 2025 against a maximum downside of 443.15% in 2025.
- A 3-year view of EBIAT shows it stood at -$33.3 million in 2023, then skyrocketed by 140.35% to $13.4 million in 2024, then plummeted by 443.15% to -$46.1 million in 2025.
- Per Business Quant, the three most recent readings for GLUE's EBIAT are -$46.1 million (Q4 2025), -$27.1 million (Q3 2025), and -$12.3 million (Q2 2025).